Anifrolumab
A monoclonal antibody that blocks the type I interferon receptor, reducing the excessive immune activation that drives tissue damage in systemic lupus erythematosus. It is given by intravenous infusion to help control lupus disease activity.
Therapeutische Bereiche
Wirkmechanismus
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A monoclonal antibody that blocks the type I interferon receptor, reducing the excessive immune activation that drives tissue damage in systemic lupus erythematosus. It is given by intravenous infusion to help control lupus disease activity.
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Yes, Anifrolumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2364653. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="anifrolumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/anifrolumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/anifrolumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/anifrolumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="anifrolumab"></drugfyi-drug>